Sebelius & DeParle
- Thread starter MarchIoda
- Start date
- Joined
- Oct 28, 2008
- Messages
- 2,569
- Reaction score
- 40
- Points
- 4,621
- Fellow [Any Field]
Sebelius is very much in favor of cost-cutting via the mid-level provider. She recently exempted CRNA's in Kansas from anesthesiologist supervision.
She seems very susceptible to lobbying, and seems willing to cut costs based on biased data. I think that the "super tech" may become a real threat that has to be dealt with.
DeParle is a major player with PBMs (specifically Medco).
The combination of these two could bode very poorly for pharmacy.
She seems very susceptible to lobbying, and seems willing to cut costs based on biased data. I think that the "super tech" may become a real threat that has to be dealt with.
DeParle is a major player with PBMs (specifically Medco).
The combination of these two could bode very poorly for pharmacy.
Last edited:
Heh, CRNAs with no MDA supervision. Can't wait until RNs bust out the scalpel. Sure, she might not know anything about anatomy or biochemistry or pathology, but she just knows she can do as good as the surgeon!